PharmaEssentia announced that it has won the "Therapeutics Solution of the Year" award at the second annual BioTech Breakthrough Awards in the United States. PharmaEssentia is the only Taiwanese biotech drug company to receive the award.
The BioTech Breakthrough Awards are presented annually by BioTech Breakthrough to the most innovative biotech companies and products with the best solutions in the industry, and this year over 1,350 companies from 12 countries around the world participated in the competition. The categories were thoroughly analysed and evaluated by a panel of industry experts in the fields of technology, business, academia and marketing, and were judged on innovation, utility, ease of use and manageability, functionality, and value and impact on society.
In particular, the new drug Besremi® (Ropeginterferon alfa-2b-njft, Ropeg, or P1101), which was developed and manufactured in-house, was awarded the "Therapeutic Drug of the Year Award" in the Biotechnology Breakthrough Awards in its first year on the market in the United States, signifying that the product's post-marketing performance, impact and potential are highly regarded worldwide. The product is highly regarded worldwide for its performance, impact and potential. The award recognises Pharmavax's commitment to providing new treatment options for the myeloproliferative neoplasm (MPN) community, as there is a growing trend in the treatment of individual patients in rare diseases.
PharmaEssentia was awarded the National Organization for Rare Disorders® (NORD®) Industry Innovation Award in March this year for its new drug, Ropeg, for the treatment of Polycythemia Vera (PV), a rare blood cancer, and the 2022 Rare Disease Impact Award in June this year. The award was also presented at the 2022 Rare Disorders Impact Awards in June this year. This year, the company also won the "Therapeutic Drug of the Year" award at the Biotechnology Breakthrough Awards. The two consecutive international awards in one year not only raise the international status of Taiwan biotech companies, but are also the first of their kind in Taiwan, and show the world the power of Taiwan's biotech research and development.
According to BioTech Breakthrough, there is a long-standing unmet need in the PV community, and Ropeg's commitment to research and development and passion to serve the PV community has redefined the treatment goals and changed the treatment paradigm for PV. Currently, Ropeg has been approved by the European Union, Taiwan, Switzerland, Israel, Korea and the United States, and is in the process of applying for a Japanese drug license, and is available in dozens of countries worldwide. Taiwan Can Help, Taiwan is Helping is truly the next step in protecting the country.
Last year, a number of major international pharmaceutical companies received the Biotechnology Breakthrough Award, including Pfizer, which has developed a vaccine with 95% protection against neostriatal disease; Gilead, which has received the first US FDA approval for the emergency use of Remdesivir for neostriatal disease; and Amgen, which has received the first US FDA approval for a new drug targeting KRAS. Amgen for Lumakras.
